Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells

Electrochemical simulation of metabolic reduction and conjugation reactions of unsymmetrical bisacridine antitumor agents, C-2028 and C-2053

(2021) Agnieszka Potęga et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

New Unsymmetrical Bisacridine Derivatives Noncovalently Attached to Quaternary Quantum Dots Improve Cancer Therapy by Enhancing Cytotoxicity toward Cancer Cells and Protecting Normal Cells

(2020) Joanna Pilch et al.   ACS Applied Materials & Interfaces

The “Green” FMOs: Diversity, Functionality and Application of Plant Flavoproteins

(2020) Sara Thodberg et al.   Catalysts

Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugs’ Cytotoxicity, Metabolism and Cellular Response

(2020) Monika Pawłowska et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes

(2020) Ewa Paluszkiewicz et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease

(2019) Ian R. Phillips et al.   XENOBIOTICA

Enzymatically Produced Trimethylamine N-Oxide: Conserving It or Eliminating It

(2019) Gianluca Catucci et al.   Catalysts

Determination of pKa(s) of nilutamide through UV-visible spectroscopy

(2018) Fernando V.L. Silva et al.   MICROCHEMICAL JOURNAL

Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems

(2018) Anna Bejrowska et al.   Pharmacological Reports

Drug-drug interaction potential of antitumor acridine agent C-1748: the substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7

(2018) Anna Mróz et al.   Pharmacological Reports

Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometry

(2018) Agnieszka Potęga et al.   XENOBIOTICA

UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: A systematic review of UGT isoforms for precision medicine

(2017) Na Yang et al.   PHARMACOLOGICAL RESEARCH

Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer

(2017) R. L. Capizzi et al.   JOURNAL OF CLINICAL ONCOLOGY

C-1311, a novel inhibitor of FLT3 and topoisomerase II: A phase 1 trial of a once every three week schedule in patients with advanced solid tumors

(2017) A. L. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

CYP2C19 drug-drug and drug-gene interactions in ED patients

(2016) Hanna K. Flaten et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

The role of glucuronidation in drug resistance

(2016) Zofia Mazerska et al.   PHARMACOLOGY & THERAPEUTICS

Principal component analysis: a review and recent developments

(2016) Ian T. Jolliffe et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES

Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells

(2015) Anna Skwarska et al.   BIOCHEMICAL PHARMACOLOGY

UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin

(2015) Ryoichi Fujiwara et al.   Drug Metabolism and Pharmacokinetics

CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells

(2013) Monika Pawłowska et al.   ACTA PHARMACOLOGICA SINICA

Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells

(2013) Ewa Augustin et al.   CELL BIOLOGY INTERNATIONAL

Potential DNA Bis-Intercalating Agents. Synthesis and Antitumor Activity of N,N'-(Methylenedi-4,1-cyclohexanediyl-bis(9-acridinamine) Isomers

(2013) Gordon W. Gribble et al.   HETEROCYCLES

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients

(2013) Ling-Zhi Wang et al.   PLoS One

Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells

(2012) Anita Wiśniewska et al.   BIOCHEMICAL PHARMACOLOGY

Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity

(2012) Porntipa Korprasertthaworn et al.   BIOCHEMICAL PHARMACOLOGY

Rapid Determination of Ionization Constants (pKa) by UV Spectroscopy Using 96-Well Microtiter Plates

(2012) Carlos H. Ríos Martínez et al.   ACS Medicinal Chemistry Letters

Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis

(2011) Jolanta Paradziej-Łukowicz et al.   CANCER BIOLOGY & THERAPY

The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s

(2011) A. Potega et al.   DRUG METABOLISM AND DISPOSITION

PharmGKB summary

(2011) Stuart A. Scott et al.   Pharmacogenetics and Genomics

CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer

(2011) Kenichi Sakurai et al.   SURGERY TODAY

Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues

(2011) Michael H. Court et al.   XENOBIOTICA

Antitumor 1-nitroacridine derivative C-1748, induces apoptosis, necrosis or senescence in human colon carcinoma HCT8 and HT29 cells

(2009) Ewa Augustin et al.   BIOCHEMICAL PHARMACOLOGY

Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours

(2009) N. Isambert et al.   EUROPEAN JOURNAL OF CANCER

Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction

(2008) S. Ohno et al.   DRUG METABOLISM AND DISPOSITION

Reactivity of adrenaline toward alkoxyl radicals and carbonyl triplet states

(2008) Gonzalo Cosa et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases

(2008) A.-S. Patana et al.   PROTEIN ENGINEERING DESIGN & SELECTION